Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Gilead Sciences Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts payable	833)	550)	905)	705)	844)
Accrued rebates	3,892)	3,802)	3,479)	3,244)	3,460)
Current portion of long-term debt and other obligations, net	1,815)	1,798)	2,273)	1,516)	2,757)
Compensation and employee benefits	1,228)	1,201)	1,018)	927)	864)
Income taxes payable	1,646)	1,208)	959)	539)	598)
Allowance for sales returns	321)	387)	422)	499)	587)
Accrual for settlement related to bictegravir litigation	—)	—)	—)	1,250)	—)
Other	2,269)	2,334)	2,181)	2,930)	2,287)
Other current liabilities	5,464)	5,130)	4,580)	6,145)	4,336)
Current liabilities	12,004)	11,280)	11,237)	11,610)	11,397)
Long-term debt, net, excluding current portion	24,896)	23,189)	22,957)	25,179)	28,645)
Long-term income taxes payable	830)	2,039)	3,916)	4,767)	5,016)
Deferred tax liability	724)	1,588)	2,673)	4,356)	3,914)
Other long-term obligations	1,295)	1,280)	1,179)	976)	1,214)
Long-term liabilities	27,745)	28,096)	30,725)	35,278)	38,789)
Total liabilities	39,749)	39,376)	41,962)	46,888)	50,186)
Preferred stock, par value $0.001 per share; none outstanding	—)	—)	—)	—)	—)
Common stock, par value $0.001 per share	1)	1)	1)	1)	1)
Additional paid-in capital	7,700)	6,500)	5,550)	4,661)	3,880)
Accumulated other comprehensive income (loss)	132)	28)	2)	83)	(60)
Retained earnings	11,497)	16,304)	15,687)	16,324)	14,381)
Total Gilead stockholders’ equity	19,330)	22,833)	21,240)	21,069)	18,202)
Noncontrolling interest	(84)	(84)	(31)	(5)	19)
Total stockholders’ equity	19,246)	22,749)	21,209)	21,064)	18,221)
Total liabilities and stockholders’ equity	58,995)	62,125)	63,171)	67,952)	68,407)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Gilead Sciences Inc. current liabilities increased from 2022 to 2023 and from 2023 to 2024.
Long-term liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Gilead Sciences Inc. long-term liabilities decreased from 2022 to 2023 and from 2023 to 2024.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Gilead Sciences Inc. total liabilities decreased from 2022 to 2023 but then slightly increased from 2023 to 2024.
Total Gilead stockholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Gilead Sciences Inc. total Gilead stockholders’ equity increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.

Gilead Sciences Inc. (NASDAQ:GILD)

Balance Sheet: Liabilities and Stockholders’ Equity